Monoethanolamine Treatment of Fish Wastes and Salmon Guts to Increase It Palmitoylethanolamide and Anandamide Contents

Abstract

This study was carried out to determine the palmitoylethanolamide (PEA) and arachidonoylethanolamide (AEA) or anandamide contents in selected fish wastes, treating the fish wastes with highest PEA and AEA with different concentration of monoethanolamine (MEA) solution, incubation temperature and time, as well as the ratio of MEA solution to fish waste to further increase its PEA and AEA contents. Based on the results of the preliminary experiment, a fractional factorial design experiments was done with 4 factors including MEA concentration, incubation time, incubation temperature and dosing ratio (MEA solution:salmon guts). The results showed that the MEA content ranged from 2.25 to 8.06 mg/g sample, the PEA content ranged from 17.4 to 300.2 µg/g sample while the AEA content ranged from 1.3 to 19.0 µg/g sample all on a wet weight basis of all the FD treated samples. The FD treated sample with the highest MEA, PEA and AEA using an MEA solution concentration of 250mM from pure MEA chemical, incubation time of 0.5 hour, incubation temperature of 6oC and a dose ratio of 6 mL MEA solution:100 g salmon guts. The MEA, PEA and AEA contents of the different samples were analysed using the Yates algorithm to determine which of the four factors were more important. The results showed that MEA, PEA and AEA contents were significantly affected by the concentration of MEA solution used in dosing the salmon guts, followed by the incubation time and then a slight effect of dosing ratio while the incubation temperature has no significant effect.

Keywords

• Monoethanolamine
• HPLC-UV
• Palmitoylethanolamide
• Anandamide
• Fish Wastes
• Salmon Guts

References

1. Abramo F, Campora L, Albanese F, Della Valle MF, Cristino L, Petrosino S, Di Marzo V, Miragliotta V 2014. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Veterinary Research. 10: 21-29.
2. Arvanitoyannis IS, Kassaveti A 2008. Fish industry waste: Treatments, environmental impacts, current and potential uses. Journal of Food Science and Technology. 43: 726-745.
3. Bayewitch M, Avidor-Reiss T, Levy R, Mechoulam R, Barg J, Vogel, Z 1995. Activation of the peripheral cannabinoid receptor (CB2) inhibits adenyl cyclase. Society of Neuroscience Abstracts. 21: 2608.
4. Cawthron Institute. 2009. Determination of fatty acid ethanolamides by LC-MS. Cawthron Quality Systems Manual 20 Method 40.113. Nelson, New Zealand. 11 pp.
5. Cerrato S, Brazis P, Della Valle, MF, Miolo A, Puigdemont A (2010). Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Veterinary Immunology and Immunopathology. 133: 9-15.
6. Costa B, Comelli F, Bettoni I, Coleoni M, Giagnoni G (2008). The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: Involvement of CB1, TRPV1 and PPAR٧receptors and neurotrophic factors. Pain. 139: 541-550.
7. Costa B, Conti S, Giagnoni G, Colleoni M 2002. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo-oxygenase systems. British Journal of Pharmacology. 137-413-420.
8. Della Rocca G., Gamba D 2021. Chronic pain in dogs and cats: Is there a place for dietary intervention with micro-palmitoylethanolamide? Animals. 11: 952 (31 pp.). doi.org//10.3390/ani11040952.

9. De Luca L, Ferracane R, Vitaglione P 2019. Food database of N-acyl-phosphatidylethanolamines, N-acylethanolamines and endocannabinoids and daily intake from a western, a Mediterranean and a vegetarian diet. Food Chemistry. 300: 125218. 9 pp.
10. Di Marzo V. 1998. Endocannbinoids and other fatty acid derivatives with cannabimemitec properties: biochemistry and possible physiopathological relevance. Biochimica Biophysics Acta. 1392: 153-175.
11. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J, Piomelli D 1994. Formation and inactivation of the endogenous cannabinoid anandamide in central neurons. Nature. 372: 686-691.
12. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, Petrocellis L 2001. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemistry Journal. 348: 249-255.
13. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S 2011. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behaviour and Immunology. 25: 1099-1112.
14. Esposito G, Pesce M, Seguella L, Lu J, Corpetti C, Del Re A, De Palma FDE, Esposito G, Sanseverino W, Sarnelli G 2021. Engineered Lactobacillus paracasei producing palmitoylethanolamide (PEA) prevents colitis in mice. International Journal of Molecular Sciences. 22: 1-14.
15. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A 1995. Mast cell express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Science (USA). 92: 3376-3380.
16. Fride E, Mechoulam R 1993. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology. 23: 313-314.
17. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry. 232: 54-61.
18. Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S 2008. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. Journal of Pharmacology and Experimental Therapy. 326: 12-23.
19. Hansen HS 2010. Palmitoylethanolamide and other anandamide congeners. Propose role in the diseased brain. Experiments in Neurology. 224: 48-55.
20. Herzberg U, Eliav E, Bennett JG, Kopin IJ 1997. The analgesic effects of R(+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters. 221: 157-160.
21. Howlett AC 1995. Pharmacology of cannabinoid receptors. Annual Review in Pharmacology and Toxicology. 35: 607-634. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC. 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76: 189-199.
22. Knaak JB, Leung HW, Stott WT, Busch J, Bilsky J 1997. Toxicology of mono-, di- and triethanolamine. Reviews in Environmental Contaminants Toxicology. 149: 1-86.
23. Kim SK, Mendis E 2006. Bioactive compounds from marine processing by-products – A review. Food Research International. 39: 383-393.
24. Larsen L, Sansom C 2008. Analysis of MEA in oil: Method development. Commercial Project with Seperex Nutritionals Ltd, Dunedin, New Zealand. 5 pp.
25. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A 1996. Nerve growth factor: from neurotrophin to neurokine. Trends in Neuroscience. 19: 514-520.
26. Liu N, Yang J, Liu YQ, Qi W 2009. Determination of monoethanolamine by HPLC with pre-column derivatization. Contemporary Chemical Industries. 4.
27. Mahro B, Timm M 2007. Potential of biowaste from the food industry as a biomass resource. Engineering in Life Sciences. 7: 457-468.
28. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346: 561-564.
29. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A 1996. N-(2-Hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. European Journal of Pharmacology. 300: 227-236.
30. Mechoulam R, Shabat SB, Hanus L, Fride E, Vogel Z, Bayewitch M, Sulcova AE 1996. Endogenous cannabinoid ligands – chemical and biological studies. Journal of Lipid Mediation and Cell Signal. 14: 45-49. Munro S, Thomas KL, Abu-Shaar M 1993. Molecular characterisation of a peripheral receptor for cannabinoids. Nature. 365: 61-65.
31. Myers RH, Montgomery DC, Anderson-Cook CM 2009. Response Surface Methodology – Process and Product Optimization Using Designed Experiments. John Wiley & Sons Inc., Hoboken, New Jersey, USA. 681 pp.
32. Natarajan V, Reddy PV, Schmid PC, Schmid HHO 1982. N-Acylationof ethanolaminephospholipids in canine myocardium. Biochima Biophysica Acta. 712: 342-355.
33. Ngim KK, Zynger J, Downey B 2007. Analysis of monoethanolamine by derivatization with Marfey’s reagent and HPLC. Journal of Chromatographic Science. 45: 126-130.
34. Passavanti MB, Alfieri A, Pace MC, Pota V, Sansone P, Piccinno G, Barbarisi M, Aurrilio C, Fiore M 2019. Clinical applications of palmitoylethanolamide in pain management: Protocol for a scoping review. Systematic Reviews. 8: 9-12.
35. Pertwee R 1993. The evidence for the existence of cannabinoid receptors. General Pharmacology. 24: 811-824. Petrosino S, Di Marzo V 2017. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology. 174: 1349-1365.
36. Schmid HHO 2000. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chemistry and Physics of Lipids. 108: 71-87.
37. Schmid HHO, Berdyshev EV 2002. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins, Leukotrienes and Essential Fatty Acids. 66: 363-376.
38. Schmid HHO, Schmid PC, Natarjan V. 1990. N-acylated glycerolipids and their derivatives. Progress in Lipid Research. 29: 1-43.
39. Seperex Nutritionals. 2008. An enrichment process and product – A Method of elevating fatty acid amide levels in cellular tissue and related products. Pending Patent Application WO2008/075978. New Zealand Patents Provisional Specification. 23 pp.
40. Shahidi F, Varatharajan V, Peng H, Senadheera R 2019. Utilization of marine by-products for the recovery of value-added products. Journal of Food Bioactives. 6: 10-61.
41. Shavandi A, Hou Y, Carne A, McConnell M, Bekhit AE 2019. Marine waste utilization as a source of functional and health compounds. In Advances in Food and Nutrition Research. Elsevier, Amsterdam, The Netherlands. Volume 87, pp. 187-254.
42. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapy. 270: 219-227.
43. Stein EA, Fuller SA, Edgemond WS, Campbell WB 1996. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in rat. British Journal of Pharmacology. 119: 107-114.
44. Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K 2000. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor: Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. Journal of Biological Chemistry. 275: 605-612.
45. Supap T, Idem R, Tontiwachwuthikul P, Saiwan C 2006. Analysis of monoethanolamine and its oxidative degradation products during CO2 absorption from flue gases: A comparative study of GC-MS, HPLC-RID and CE-DAD analytical techniques and possible optimum conditions. Industrial Engineering Chemical Research. 45: 2437-2451.
46. Voice A, Rochelle GT 2013. Products and process variables in oxidation of monoethanolamine for CO2 capture. International Journal of Greenhouse Gas Control. 12: 472-477.
47. Welch SP, Dunlow SD, Patrick GS, Razdan RK 1995. Characterisation of anandamide- and fluoroanandamide-induced antinociception and cross tolerance to delta-9-THC after intrathecal administration to mice: blockade of delta-9-THC-induced antinociception. Journal of Pharmacology and Experimental Therapy. 273: 1235-1244.
48. Zhao Z, Dong H, Huang Y, Cao L, Gao J, Zhang X, Zhang S 2015. Ionic degradation inhibitors and kinetic models for CO2 manufacture with aqueous monoethanolamine. International Journal of Greenhouse Gas Control. 39: 119-128.